- Home
- KLRS vs MCRB Comparison
KLRS vs MCRB Comparison
Compare KLRS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | MCRB |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 41.2M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KLRS | MCRB |
|---|---|---|
| Price | $1.55 | $1.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $16.33 | ★ $17.00 |
| AVG Volume (30 Days) | 70.4K | ★ 79.1K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.70 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $165,000.00 | ★ $789,000.00 |
| Revenue This Year | N/A | $1,648.67 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $1.30 |
| 52 Week High | $11.88 | $29.98 |
Technical Indicators
Market Signals| Indicator | KLRS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 23.02 |
| Support Level | N/A | N/A |
| Resistance Level | $2.66 | $2.26 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 10.42 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.